Correction to: Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations - Scorecard - MDSpire

Correction to: Quantitative susceptibility mapping at 7 T in COVID-19: brainstem effects and outcome associations

  • October 28, 2024

  • 0 min

Share

Clinical Scorecard: Erratum: Evaluating Brainstem Impacts and Outcome Correlations of Quantitative Susceptibility Mapping at 7 Tesla in COVID-19

At a Glance

CategoryDetail
ConditionNeurological impacts of COVID-19 on the brainstem
Key MechanismsQuantitative susceptibility mapping (QSM) at 7 Tesla MRI to assess brainstem changes
Target PopulationPatients with COVID-19
Care SettingResearch and clinical neuroimaging settings

Key Highlights

  • QSM at 7T used to evaluate brainstem effects in COVID-19 patients
  • Outcome associations of brainstem changes identified via advanced imaging
  • Corrections issued regarding acknowledgements and funding disclosures

Guideline-Based Recommendations

Diagnosis

  • Utilize high-field 7 Tesla MRI with quantitative susceptibility mapping for detailed brainstem assessment in COVID-19 neurological studies

Management

    Monitoring & Follow-up

      Risks

        Patient & Prescribing Data

        COVID-19 patients undergoing neurological evaluation

        No direct treatment recommendations; imaging findings may inform prognosis and research

        Clinical Best Practices

        • Ensure accurate and comprehensive acknowledgements and funding disclosures in research publications
        • Adopt advanced neuroimaging techniques like QSM at 7T for detailed brainstem evaluation in COVID-19
        • Collaborate across research centers and maintain rigorous ethical and procedural standards during pandemic conditions

        References

        Original Source(s)

        Related Content